IDH Inhibitor Use in Patients with Relapsed or Refractory AML
April 15th 2019In this clip, Bernard Marini, PharmD, BCOP, inpatient hematology specialist at the University of Michigan, discusses how IDH inhibitors like ivosidenib and enasidenib fit into the treatment landscape for patients with relapsed or refractory acute myeloid leukemia.
Read More
Considerations for Apalutamide Versus Enzalutamide in Prostate Cancer Treatment
April 9th 2019Lisa Holle, PharmD, BCOP, FHOPA, associate clinical professor at the University of Connecticut, explains which patient populations would best benefit from either apalutamide versus enzalutamide in the treatment of non-metastatic prostate cancer.
Read More
Technology Aims to Prevent Drug Diversion
January 30th 2019Recognizing the ongoing opioid crisis and the need to deter theft of drugs, at least 2 medical technology companies—BD and Invistics—have come up with promising digital solutions that track how medications are being dispensed.
Read More
Drug Shortages and Antibiotic Delivery: What Has the Impact Been?
December 20th 2018Although there are some advantages and disadvantages to both routes of antibiotic administration, several factors must be considered when determining the best antibiotic delivery method for the patient, including cost, effort of administration, and safety risks.
Read More